Aggressive Non-Hodgkin Lymphoma during pregnancy

  • Carolina Córdoba Universidad de la República, Facultad de Medicina, Hospital de Clínicas, Cátedra de Hematología. Residente
  • Florencia Laluz Universidad de la República, Facultad de Medicina, Hospital de Clínicas, Cátedra de Hematología. Posgrado
  • Isabel Moro Universidad de la República, Facultad de Medicina, Hospital de Clínicas, Cátedra de Hematología. Asistente
  • Hugo Isaurralde Universidad de la República, Facultad de Medicina, Hospital de Clínicas, Cátedra de Hematología. Prof. Agdo
  • Lilián Díaz Universidad de la República, Facultad de Medicina, Hospital de Clínicas, Cátedra de Hematología. Prof. Titular
Keywords: NON HODGKIN LYMPHOMA, PREGNANCY COMPLICATIONS

Abstract

Clinical case of a 26 year old patient who presented at 32 weeks of gestational age and was diagnosed with diffuse large B-cell non-Hodgkin lymphoma (DLBCL).
The present communication is interesting given the low frequency of cases and, as a consequence, the scarce experience regarding such association in our country and around the world.
In the following case we aim to analyze the diagnostic steps, stadification, prognostic factors and treatment of non-Hodgkin lymphoma during pregnancy and breastfeeding.

 

References

(1) Pereg D, Koren G, Lishner M. The treatment of Hodgkin’s and non-Hodgkin’s lymphoma in pregnancy. Haematologica 2007; 92(9): 1230-7
(2) Weisz B, Schiff E, Lishner M. Cancer in pregnancy: maternal and fetal implications. Hum Reprod Update 2001; 7(4): 384-93.
(3) Monleón J, Goberna L, Monleón FJ. Cáncer y gestación. Clin Invest Ginecol Obst 2006; 33(3): 80-92.
(4) Tartas NE, Foncuberta MC, Sánchez Avalos JC. Tratamiento de las neoplasias hematológicas en el embarazo. Medicina (B. Aires) 2007; 67(6): 729-36.
(5) World Health Organization. WHO Classification of tumours of haematopoietic and lymphoid tissue. 4 ed. Geneve: WHO, 2008.
(6) Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109(5): 1857-61.
(7) Serrano S, Besses C, Domínguez D. Linfomas no hodgkinianos bases citoevolutivas y funcionales: clasificación y descripción de sus distintas variedades. In: Sans-Sabrafen J, Besses Raebel C, Vives Corrons J. Hematología Clínica. 4 ed. Madrid: Elsevier, 2006: 501-35.
(8) Sivanesaratnam V. Management of the pregnant mother with malignant conditions. Curr Opin Obstet Gynecol 2001; 13(2): 121-5.
(9) Pavlidis NA. Coexistence of pregnancy and malignancy. Oncologist 2002; 7(4): 279-87.
(10) Avilés A, Neri N, Nambo MJ. Long-term evaluation of cardiac function in children who received anthracyclines during pregnancy. Ann Oncol 2006; 17(2): 286-8.
(11) Friedrichs B, Tiemann M, Salwender H, Verpoort K, Wenger MK, Schmitz N. The effects of rituximab treatment during pregnancy on a neonate. Haematologica 2006; 91(10): 1426-7.
(12) Gwyn K. Children exposed to chemotherapy in utero. J Natl Cancer Inst Monogr 2005; (34): 69-71.
Published
2010-06-30
How to Cite
1.
Córdoba C, Laluz F, Moro I, Isaurralde H, Díaz L. Aggressive Non-Hodgkin Lymphoma during pregnancy. Rev. Méd. Urug. [Internet]. 2010Jun.30 [cited 2024May18];26(2):102-7. Available from: http://www2.rmu.org.uy/ojsrmu311/index.php/rmu/article/view/434